Home >> Research Area >>Others>>Others>> L-Thyroxine sodium salt pentahydrate

L-Thyroxine sodium salt pentahydrate

Thyroid hormone CAS# 6106-07-6

L-Thyroxine sodium salt pentahydrate

Catalog No. BCC4283----Order now to get a substantial discount!

Product Name & Size Price Stock
L-Thyroxine sodium salt pentahydrate:500mg $38.00 In stock
L-Thyroxine sodium salt pentahydrate:1000mg $65.00 In stock
L-Thyroxine sodium salt pentahydrate:2500mg $152.00 In stock
L-Thyroxine sodium salt pentahydrate:5000mg $266.00 In stock
Molarity Calculator Dilution Calculator Send Mail Directly
Related Products

Quality Control of L-Thyroxine sodium salt pentahydrate

Quality Control & MSDS

Number of papers citing our products

Chemical structure

L-Thyroxine sodium salt pentahydrate

3D structure

Chemical Properties of L-Thyroxine sodium salt pentahydrate

Cas No. 6106-07-6 SDF Download SDF
PubChem ID 23665037 Appearance Powder
Formula C15H20I4NNaO9 M.Wt 888.93
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Sodium levothyroxine pentahydrate
Solubility DMSO : ≥ 28 mg/mL (31.50 mM);
Chemical Name sodium;(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;pentahydrate
SMILES C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)[O-])N.O.O.O.O.O.[Na+]
Standard InChIKey JMHCCAYJTTWMCX-QWPJCUCISA-M
Standard InChI InChI=1S/C15H11I4NO4.Na.5H2O/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;;;;;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);;5*1H2/q;+1;;;;;/p-1/t12-;;;;;;/m0....../s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of L-Thyroxine sodium salt pentahydrate

DescriptionL-Thyroxine sodium salt pentahydrate (Levothyroxine; T4) is a synthetic hormone in the treatment of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4).In Vivo:Deiodinases (DIOs), which catalyse the conversion of thyroxine (pro-hormone) to the active thyroid hormone, are associated with thyroid stimulating hormone (TSH) levels. DIO1 and DIO2 catalyze activation of thyroid hormone secretion in contrast to DIO3 playing role inactivation of the secretion. Activities of DIO1 and DIO2 play pivotal role in the negative feedback regulation of pituitary TSH secretion[1]. L-Thyroxine (T4) and Triiodothyronine (T3) hormones are known to modulate the expression of ionic channels, pumps and regulatory contractile proteins. Moreover, thyroid hormones have been shown to influence calcium homeostasis and flux responsible for excitation and contractility, with L-Thyroxine and Triiodothyronine modulating its pharmacological control and secretion. In rats fed 12 weeks with the iodine-free diet, a significant decrease in the levels of both Triiodothyronine and L-Thyroxine is observed when compared to the control group fed with standard diet (p<0.001). In the group treated with low doses of L-Thyroxine, an increase in L-Thyroxine levels is observed (p=0.02) while Triiodothyronine levels remain virtually similar to the control group (p=0.19). Rats treated with high doses of L-Thyroxine display a significant increase in both Triiodothyronine and L-Thyroxine circulating concentrations compared to the non-treated hypothyroid group (p<0.001 and p=0.004, respectively) and a significant increase in L-Thyroxine levels when compared to the control values (p=0.03)[2].

References:
[1]. Arici M, et al. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Jan 11. [2]. Corriveau S, et al. Levothyroxine treatment generates an abnormal uterine contractility patterns in an in vitro animalmodel. J Clin Transl Endocrinol. 2015 Sep 9;2(4):144-149.

Protocol

Animal Administration [2]
Rats[2] Sprague-Dawley female rats (N=22) are used. Non-pregnant rats are divided into four groups: 1) control, 2) hypothyroidism, 3) hypothyroidism treated with low doses of L-Thyroxine (20 μg/kg/day) and 4) with high doses of L-Thyroxine (100 μg/kg/day). Control rats (group 1) are fed with standard diet, while the intervention rats are fed with iodine-free diet for 12 weeks to induce hypothyroidism (groups 2-4) which is continued for four more weeks to allow screening of hypothyroid status and L-Thyroxine-treatment. Food and water (iodine-free diet) are available ad libitum. The hypothyroid group treated with low (group 3) or high doses of L-Thyroxine (group 4) are injected intraperitoneally every 24 h with respectively 20 μg/kg/day and 100 μg/kg/day. Blood samples are collected for thyroid function screening at week 12 and 16 following the initiation of either the control or iodine-free diet. Hysterectomy is performed under general anesthesia (isoflurane 2%) at the end of the treatment and the two uterine horns are placed in physiological Krebs' solution until isometric tension measurements within no more than 1 h.

References:
[1]. Arici M, et al. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Jan 11. [2]. Corriveau S, et al. Levothyroxine treatment generates an abnormal uterine contractility patterns in an in vitro animalmodel. J Clin Transl Endocrinol. 2015 Sep 9;2(4):144-149.

L-Thyroxine sodium salt pentahydrate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

L-Thyroxine sodium salt pentahydrate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of L-Thyroxine sodium salt pentahydrate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.1249 mL 5.6247 mL 11.2495 mL 22.499 mL 28.1237 mL
5 mM 0.225 mL 1.1249 mL 2.2499 mL 4.4998 mL 5.6247 mL
10 mM 0.1125 mL 0.5625 mL 1.1249 mL 2.2499 mL 2.8124 mL
50 mM 0.0225 mL 0.1125 mL 0.225 mL 0.45 mL 0.5625 mL
100 mM 0.0112 mL 0.0562 mL 0.1125 mL 0.225 mL 0.2812 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on L-Thyroxine sodium salt pentahydrate

L-Thyroxine is an iodine containing hormone produced from thyroglobulin in the thyroid follicular cells. L-Thyroxine reduces total cholesterol level, low-density lipoprotein cholesterol as well as waist to hip ratio in subclinical hypothyroidism pateints.

Featured Products
New Products
 

Description

L-Thyroxine sodium salt pentahydrate(Levothyroxine) is an iodine containing hormone produced from thyroglobulin in the thyroid follicular cells; reduces total cholesterol level, low-density lipoprotein cholesterol as well as waist to hip ratio in subclinical hypothyroidism pateints.

Keywords:

L-Thyroxine sodium salt pentahydrate,6106-07-6,Sodium levothyroxine pentahydrate,Natural Products,Others, buy L-Thyroxine sodium salt pentahydrate , L-Thyroxine sodium salt pentahydrate supplier , purchase L-Thyroxine sodium salt pentahydrate , L-Thyroxine sodium salt pentahydrate cost , L-Thyroxine sodium salt pentahydrate manufacturer , order L-Thyroxine sodium salt pentahydrate , high purity L-Thyroxine sodium salt pentahydrate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result:

      BioCrick BioTech
      88# Keyuan road,Hi-Tech Zone
      Chengdu, Sichuan 610042, PRC
      Email: info@biocrick.com
      Tel:86-28-8543-3893
      Follow us:

      BioCrick is one of the biggest natural products manufacturers in Asia

      Our products can be used as reference standards,inhibitors in pharmacological research

      Our MISSION is to provide Best-in-class High-purity natural compounds to researchers all around the world

      © 2007-2024 BioCrick BioTech. All rights reserved.  sitemap

      Menu Close
      Search Now